Analysis of plant-derived phytochemicals as anti-cancer agents targeting cyclin dependent kinase-2, human topoisomerase IIa and vascular endothelial growth factor receptor-2

References

• WHO. World health statistics 2006. 2006. Available from: http://www.who.int/
   Google Scholar
• Da Rocha AB, Lopes RM, Schwartsmann G. Natural products in anticancer therapy. Curr Opin Pharmacol. 2001;1:364–369.
   PubMedGoogle Scholar
• Cragg GM, Newman DJ. Plants as a source of anti-cancer agents. J Ethnopharmacol. 2005;100:72–79.
   PubMed Web of Science ®Google Scholar
• Pan L, Chai H, Kinghorn AD. The continuing search for antitumor agents from higher plants. Phytochem Lett. 2010;3:1–8.
   PubMed Web of Science ®Google Scholar
• Sarkar B, Ullah M, Islam A, et al. Anticancer potential of medicinal plants from Bangladesh and their effective compounds against cancer. J Pharmacogn Phytochem. 2019;8:827–833.
   Google Scholar
• Pan L, Chai HB, Kinghorn AD. Discovery of new anticancer agents from higher plants. Front Biosci (Schol Ed). 2012;4:4, 142–156.
   PubMedGoogle Scholar
• Fischbach MA, Walsh CT. Directing biosynthesis. Science. 2006;314:603–605.
   PubMed Web of Science ®Google Scholar
• Fabricant DS, Farnsworth NR. The value of plants used in traditional medicine for drug discovery. Environ Health Persp. 2001;109:69–75.
   PubMed Web of Science ®Google Scholar
• Tan G, Gyllenhaal C, Soejarto DD. Biodiversity as a source of anticancer drugs. Curr Drug Targets. 2006;7:265–277.
   PubMed Web of Science ®Google Scholar
• Saklani A, Kutty SK. Plant-derived compounds in clinical trials. Drug Discov Today. 2008;13:161–171.
   PubMed Web of Science ®Google Scholar
• The ASCO Post. EHA 2018: alvocidib in patients with relapsed or refractory MCL-1–dependent AML. 2018 [accessed 2020 Mar 3]. Avaiable from: https://ascopost.com/News/58966
   Google Scholar
• Mayo Clinic. Lenvatinib (oral route). [accessed 2020 Mar 3]. Available from: https://www.mayoclinic.org/drugs-supplements/lenvatinib-oral-route/side-effects/drg-20137764?p=1
   Google Scholar
• drugs.com. Daunorubicin side effects. [accessed 2020 Mar 3]. Available from: https://www.drugs.com/sfx/daunorubicin-side-effects.html
   Google Scholar
• Karimi A, Majlesi M, Rafieian-Kopaei M. Herbal versus synthetic drugs; beliefs and facts. J Nephropharmacol. 2015;4:27–30.
   PubMedGoogle Scholar
• Qi F, Yan Q, Zheng Z, et al. Geraniol and geranyl acetate induce potent anticancer effects in colon cancer Colo-205 cells by inducing apoptosis, DNA damage and cell cycle arrest. J Buon. 2018;23:346–352.
   PubMed Web of Science ®Google Scholar
• Duncan RE, Lau D, El-Sohemy A, et al. Geraniol and β-ionone inhibit proliferation, cell cycle progression, and cyclin-dependent kinase 2 activity in MCF-7 breast cancer cells independent of effects on HMG-CoA reductase activity. Biochem Pharmacol. 2004;68:1739–1747.
   PubMed Web of Science ®Google Scholar
• Amin A, Gali-Muhtasib H, Ocker M, et al. Overview of major classes of plant-derived anticancer drugs. Int J Biomed Sci. 2009;5:1–11.
   PubMedGoogle Scholar
• Ramirez-Mares MV, Chandra S, de-Mejia EG. In vitro chemopreventive activity of Camellia sinensis, Ilex paraguariensis and Ardisia compressa tea extracts and selected polyphenols. Mutat Res. 2004;554:53–65.
   PubMed Web of Science ®Google Scholar
• Ponnusamy K, Petchiammal C, Mohankumar R, et al. In vitro antifungal activity of indirubin isolated from a South Indian ethnomedicinal plant Wrightia tinctoria R. J Ethnopharmacol. 2010;132:349–354.
   PubMed Web of Science ®Google Scholar
• Jautelat R, Brumby T, Schäfer M, et al. From the insoluble dye indirubin towards highly active, soluble CDK2‐inhibitors. Chembiochem. 2005;6:531–540.
   PubMed Web of Science ®Google Scholar
• Hoessel R, Leclerc S, Endicott JA, et al. Indirubin, the active constituent of a Chinese antileukaemia medicine, inhibits cyclin-dependent kinases. Nat Cell Biol. 1999;1:60–67.
   PubMed Web of Science ®Google Scholar
• Jain SK, Bharate SB, Vishwakarma RA. Cyclin-dependent kinase inhibition by flavoalkaloids. Mini Rev Med Chem. 2012;12:632–649.
   PubMed Web of Science ®Google Scholar
• Lu X, Jung J, Cho I, et al. Fisetin inhibits the activities of cyclin-dependent kinases leading to cell cycle arrest in HT-29 human colon cancer cells. J Nutr. 2005;135:2884–2890.
   PubMed Web of Science ®Google Scholar
• Rengarajan T, Yaacob NS. The flavonoid fisetin as an anticancer agent targeting the growth signaling pathways. Eur J Pharmacol. 2016;789:8–16.
   PubMed Web of Science ®Google Scholar
• Shukla S, Gupta S. Apigenin-induced cell cycle arrest is mediated by modulation of MAPK, PI3K-Akt, and loss of cyclin D1 associated retinoblastoma dephosphorylation in human prostate cancer cells. Cell Cycle. 2007;6:1102–1114.
   PubMed Web of Science ®Google Scholar
• Lin Y, Shi R, Wang X, et al. Luteolin, a flavonoid with potential for cancer prevention and therapy. CCDT. 2008;8:634–646.
   Web of Science ®Google Scholar
• Saewan N, Koysomboon S, Chantrapromma K. Anti-tyrosinase and anti-cancer activities of flavonoids from Blumea balsamifera DC. J Med Plants Res. 2011;5:1018–1025.
   Google Scholar
• Cho HJ, Park JHY. Kaempferol induces cell cycle arrest in HT-29 human colon cancer cells. J Cancer Prev. 2013;18:257–263.
   PubMedGoogle Scholar
• Yang J, Xiao P, Sun J, et al. Anticancer effects of kaempferol in A375 human malignant melanoma cells are mediated via induction of apoptosis, cell cycle arrest, inhibition of cell migration and downregulation of m-TOR/PI3K/AKT pathway. J Buon. 2018;23:218–223.
   PubMed Web of Science ®Google Scholar
• Weng MS, Ho YS, Lin JK. Chrysin induces G1 phase cell cycle arrest in C6 glioma cells through inducing p21Waf1/Cip1 expression: involvement of p38 mitogen-activated protein kinase. Biochem Pharmacol. 2005;69:1815–1827.
   PubMed Web of Science ®Google Scholar
• Samarghandian S, Nezhad M, Mohammadi G. Role of caspases, Bax and Bcl-2 in chrysin-induced apoptosis in the A549 human lung adenocarcinoma epithelial cells. ACAMC. 2014;14:901–909.
   Google Scholar
• Khan W, Ashfaq U, Aslam A, et al. Anticancer screening of medicinal plant phytochemicals against cyclin-dependent kinase-2 (CDK2): an in-silico approach. Adv Life Sci. 2017;4:113–119.
   Web of Science ®Google Scholar
• Choi YH, Lee WH, Park KY, et al. p53‐independent induction of p21 (WAF1/CIP1), reduction of cyclin B1 and G2/M arrest by the isoflavone genistein in human prostate carcinoma cells. Jpn J Cancer Res. 2000;91:164–173.
   PubMedGoogle Scholar
• Sarkar FH, Adsule S, Padhye S, et al. The role of genistein and synthetic derivatives of isoflavone in cancer prevention and therapy. Mini Rev Med Chem. 2006;6:401–407.
   PubMed Web of Science ®Google Scholar
• Grynberg NF, Carvalho MD, Velandia JR, et al. DNA topoisomerase inhibitors: biflavonoids from Ouratea species. Braz J Med Biol Res. 2002;35:819–822.
   PubMed Web of Science ®Google Scholar
• Kirby G, Paine C, Warhurst A, et al. In vitro and in vivo antimalarial activity of cryptolepine, a plant‐derived indoloquinoline. Phytother Res. 1995;9:359–363.
   Web of Science ®Google Scholar
• Bonjean K, De-Pauw-Gillet M, Defresne C, et al. The DNA intercalating alkaloid cryptolepine interferes with topoisomerase II and inhibits primarily DNA synthesis in B16 melanoma cells. Biochemistry. 1998;37:5136–5146.
   PubMed Web of Science ®Google Scholar
• Bailly C, Laine W, Baldeyrou B, et al. DNA intercalation, topoisomerase II inhibition and cytotoxic activity of the plant alkaloid neocryptolepine. Anticancer Drug Des. 2000;15:191–201.
   PubMedGoogle Scholar
• Dassonneville L, Lansiaux A, Wattelet A, et al. Cytotoxicity and cell cycle effects of the plant alkaloids cryptolepine and neocryptolepine: relation to drug-induced apoptosis. Eur J Pharmacol. 2000;409:9–18.
   PubMed Web of Science ®Google Scholar
• Sun NJ, Woo SH, Cassady JM, et al. DNA polymerase and topoisomerase II inhibitors from Psoralea corylifolia. J Nat Prod. 1998;61:362–366.
   PubMed Web of Science ®Google Scholar
• Prescott TA, Sadler IH, Kiapranis R, et al. Lunacridine from Lunasia amara is a DNA intercalating topoisomerase II inhibitor. J Ethnopharmacol. 2007;109:289–294.
   PubMed Web of Science ®Google Scholar
• Jo JY, Gonzalez-de-Mejia E, Lila MA. Catalytic inhibition of human DNA topoisomerase II by interactions of grape cell culture polyphenols. J Agric Food Chem. 2006;54:2083–2087.
   PubMed Web of Science ®Google Scholar
• Vissac-Sabatier C, Bignon YJ, Bernard-Gallon DJ. Effects of the phytoestrogens genistein and daidzein on BRCA2 tumor suppressor gene expression in breast cell lines. Nutr Cancer. 2003;45:247–255.
   PubMed Web of Science ®Google Scholar
• Sugimoto Y, Tsukahara S, Oh-Hara T, et al. Elevated expression of DNA topoisomerase II in camptothecin-resistant human tumor cell lines. Cancer Res. 1990;50:7962–7965.
   PubMed Web of Science ®Google Scholar
• Zheng MS, Lee YK, Li Y, et al. Inhibition of DNA topoisomerases I and II and cytotoxicity of compounds from Ulmus davidiana var. japonica. Arch Pharm Res. 2010;33:1307–1315.
   PubMed Web of Science ®Google Scholar
• Lu HR, Meng LH, Huang M, et al. DNA damage, c-myc suppression and apoptosis induced by the novel topoisomerase II inhibitor, salvicine, in human breast cancer MCF-7 cells. Cancer Chemother Pharmacol. 2005;55:286–294.
   PubMed Web of Science ®Google Scholar
• Zhang Y, Wang L, Chen Y, et al. Anti-angiogenic activity of salvicine. Pharm Boil. 2013;51:1061–1065.
   PubMed Web of Science ®Google Scholar
• Lee YK, Seo CS, Lee CS, et al. K. Inhibition of DNA topoisomerases I and II and cytotoxicity by lignans from Saururus chinensis. Arch Pharm Res. 2009;32:1409–1415.
   PubMed Web of Science ®Google Scholar
• Maas JL, Galletta GJ, Stoner GD. Ellagic acid, an anticarcinogen in fruits, especially in strawberries: a review. HortSci. 1991;26:10–14.
   Web of Science ®Google Scholar
• Labrecque L, Lamy S, Chapus A, et al. Combined inhibition of PDGF and VEGF receptors by ellagic acid, a dietary-derived phenolic compound. Carcinogenesis. 2005;26:821–826.
   PubMed Web of Science ®Google Scholar
• Tong Q, Qing Y, Wu Y, et al. Dioscin inhibits colon tumor growth and tumor angiogenesis through regulating VEGFR2 and AKT/MAPK signaling pathways. Toxicol Appl Pharm. 2014;281:166–173.
   PubMed Web of Science ®Google Scholar
• Cho J, Choi H, Lee J, et al. The antifungal activity and membrane-disruptive action of dioscin extracted from Dioscorea nipponica. Biochim Biophys Acta. 2013;1828:1153–1158.
   PubMed Web of Science ®Google Scholar
• Xu HY, Pan YM, Chen ZW, et al. 12-Deoxyphorbol 13-palmitate inhibit VEGF-induced angiogenesis via suppression of VEGFR-2-signaling pathway. J Ethnopharmacol. 2013;146:724–733.
   PubMed Web of Science ®Google Scholar
• Xu HY, Chen ZW, Li H, et al. 12-Deoxyphorbol 13-palmitate mediated cell growth inhibition, G2-M cell cycle arrest and apoptosis in BGC823 cells. Eur J Pharmacol. 2013;700:13–22.
   PubMed Web of Science ®Google Scholar
• Cerezo A, Hornedo-Ortega R, Álvarez-Fernández M, et al. Inhibition of VEGF-induced VEGFR-2 activation and HUVEC migration by melatonin and other bioactive indolic compounds. Nutrients. 2017;9:249.
   Web of Science ®Google Scholar
• Plaimee P, Weerapreeyakul N, Barusrux S, et al. Melatonin potentiates cisplatin‐induced apoptosis and cell cycle arrest in human lung adenocarcinoma cells. Cell Prolif. 2015;48:67–77.
   PubMed Web of Science ®Google Scholar
• Mu X, Shi W, Sun L, et al. Pristimerin, a triterpenoid, inhibits tumor angiogenesis by targeting VEGFR2 activation. Molecules. 2012;17:6854–6868.
   PubMed Web of Science ®Google Scholar
• Hayashi D, Shirai T, Terauchi R, et al. Pristimerin inhibits the proliferation of HT1080 fibrosarcoma cells by inducing apoptosis. Oncol Lett. 2020;19:2963–2970.
   PubMed Web of Science ®Google Scholar
• Saraswati S, Kumar S, Alhaider AA. α-Santalol inhibits the angiogenesis and growth of human prostate tumor growth by targeting vascular endothelial growth factor receptor 2-mediated AKT/mTOR/P70S6K signaling pathway. Mol Cancer. 2013;12:147.
   PubMed Web of Science ®Google Scholar
• Lai L, Liu J, Zhai D, et al. Plumbagin inhibits tumour angiogenesis and tumour growth through the Ras signalling pathway following activation of the VEGF receptor‐2. Brit J Pharmacol. 2012;165:1084–1096.
   PubMed Web of Science ®Google Scholar
• Jung MH, Lee SH, Ahn EM, et al. Decursin and decursinol angelate inhibit VEGF-induced angiogenesis via suppression of the VEGFR-2-signaling pathway. Carcinogenesis. 2009;30:655–661.
   PubMed Web of Science ®Google Scholar
• Jung SY, Choi JH, Kwon SM, et al. Decursin inhibits vasculogenesis in early tumor progression by suppression of endothelial progenitor cell differentiation and function. J Cell Biochem. 2012;113:1478–1487.
   PubMed Web of Science ®Google Scholar
• Xia Y, Min KH, Lee K. Synthesis and biological evaluation of decursin, prantschimgin and their derivatives. Bull Korean Chem Soc. 2009;30:43–48.
   Web of Science ®Google Scholar
• Lee S, Lee Y, Jung S, et al. Anti-tumor activities of decursinol angelate and decursin from Angelica gigas. Arch Pharm Res. 2003;26:727–730.
   PubMed Web of Science ®Google Scholar
• Pratheeshkumar P, Budhraja A, Son Y, et al. Quercetin inhibits angiogenesis mediated human prostate tumor growth by targeting VEGFR-2 regulated AKT/mTOR/P70S6K signaling pathways. PloS ONE. 2012;7:e47516.
   PubMed Web of Science ®Google Scholar
• Miean KH, Mohamed S. Flavonoid (myricetin, quercetin, kaempferol, luteolin, and apigenin) content of edible tropical plants. J Agric Food Chem. 2001;49:3106–3112.
   PubMed Web of Science ®Google Scholar
• Le Son H, Anh NP. Phytochemical composition, in vitro antioxidant and anticancer activities of quercetin from methanol extract of Asparagus cochinchinensis (Lour.) Merr. Tuber. J Med Plants Res. 2013;7:3360–3366.
   Google Scholar
• Nevins J, Leone R, DeGregori G, et al. Role of the Rb/E2F pathway in cell growth control. J Cell Physiol. 1997;173:233–236.
   PubMed Web of Science ®Google Scholar
• De-Bondt H, Rosenblatt L, Jancarik J, et al. Crystal structure of cyclin-dependent kinase 2. Nature. 1993;363:595–602.
   PubMed Web of Science ®Google Scholar
• Sherr C, Roberts JM. CDK inhibitors: positive and negative regulators of G1-phase progression. Gene Dev. 1999;13:1501–1512.
   PubMed Web of Science ®Google Scholar
• Ho A, Dowdy S. F. Regulation of G1 cell-cycle progression by oncogenes and tumor suppressor genes. Curr Opin Genet Dev. 2002;12:47–52.
   PubMed Web of Science ®Google Scholar
• Shapiro G. I. Cyclin-dependent kinase pathways as targets for cancer treatment. J Clin Oncol. 2006;24:1770–1783.
   PubMed Web of Science ®Google Scholar
• Boonstra J. Progression through the G1‐phase of the on‐going cell cycle. J Cell Biochem. 2003;90:244–252.
   PubMed Web of Science ®Google Scholar
• Harper JW, Elledge SJ. Cdk inhibitors in development and cancer. Curr Opin Genet Dev. 1996;6:56–64.
   PubMed Web of Science ®Google Scholar
• Ullah A, Prottoy N, Araf I, et al. Molecular docking and pharmacological property analysis of phytochemicals from Clitoria ternatea as potent inhibitors of cell cycle checkpoint proteins in the cyclin/CDK pathway in cancer cells. CMB. 2019;09:81–94.
   Google Scholar
• Benson C, Kaye S, Workman P, et al. Clinical anticancer drug development: targeting the cyclin-dependent kinases. Br J Cancer. 2005;92:7–12.
   PubMed Web of Science ®Google Scholar
• Deweese JE, Osheroff N. The DNA cleavage reaction of topoisomerase II: wolf in sheep’s clothing. Nucleic Acids Res. 2009;37:738–748.
   PubMed Web of Science ®Google Scholar
• Nitiss JL. Targeting DNA topoisomerase II in cancer chemotherapy. Nat Rev Cancer. 2009;9:338–350.
   PubMed Web of Science ®Google Scholar
• Russo P, Del-Bufalo A, Cesario A. Flavonoids acting on DNA topoisomerases: recent advances and future perspectives in cancer therapy. CMC. 2012;19:5287–5293.
   PubMed Web of Science ®Google Scholar
• Ashour ME, Atteya R, El-Khamisy SF. Topoisomerase-mediated chromosomal break repair: an emerging player in many games. Nat Rev Cancer. 2015;15:137–151.
   PubMed Web of Science ®Google Scholar
• Christmann-Franck S, Bertrand H, Goupil-Lamy O, et al. Structure-based virtual screening: an application to human topoisomerase II α. J Med Chem. 2004;47:6840–6853.
   PubMed Web of Science ®Google Scholar
• Folkman J. 1984. Angiogenesis. In: Jaffe EA, editor. Biology of endothelial cells. Boston (MA): Springer; p. 412–428.
   Google Scholar
• Ferrara N, Davis-Smyth T. The biology of vascular endothelial growth factor. Endocr Rev. 1997;18:4–25.
   PubMed Web of Science ®Google Scholar
• Nowak D, Woolard G, Amin J, et al. Expression of pro-and anti-angiogenic isoforms of VEGF is differentially regulated by splicing and growth factors. J Cell Sci. 2008;121:3487–3495.
   PubMed Web of Science ®Google Scholar
• Kim K, Li J, Winer B, et al. Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo. Nature. 1993;362:841–844.
   PubMed Web of Science ®Google Scholar
• Ma X, Ma CX, Wang J. Endometrial carcinogenesis and molecular signaling pathways. AJMB. 2014;04:134–149.
   Google Scholar
• Rini BI. Vascular endothelial growth factor–targeted therapy in renal cell carcinoma: current status and future directions. Clin Cancer Res. 2007;13:1098–1106.
   PubMed Web of Science ®Google Scholar
• Melincovici CS, Boşca AB, Şuşman S, et al. Vascular endothelial growth factor (VEGF)-key factor in normal and pathological angiogenesis. Rom J Morphol Embryol. 2018;59:455–467.
   PubMed Web of Science ®Google Scholar
• Tahara M, Kiyota N, Yamazaki T, et al. Lenvatinib for anaplastic thyroid cancer. Front Oncol. 2017;7:25.
   PubMed Web of Science ®Google Scholar
• Roskoski R. Jr, Vascular endothelial growth factor (VEGF) and VEGF receptor inhibitors in the treatment of renal cell carcinomas. Pharmacol Res. 2017;120:116–132.
   PubMed Web of Science ®Google Scholar
• Schrödinger Release 2018-4: Protein Preparation Wizard; Epik, Schrödinger, LLC, New York, NY, 2016; Impact, Schrödinger, LLC, New York, NY, 2016; Prime, Schrödinger, LLC, New York, NY; 2018.
   Google Scholar
• Schrödinger Release 2018-4: Prime. New York (NY): Schrödinger, LLC; 2018.
   Google Scholar
• Schrödinger Release 2018-4: LigPrep. New York (NY): Schrödinger, LLC; 2018.
   Google Scholar
• Schrödinger Release 2018-4: Epik. New York (NY): Schrödinger, LLC; 2018.
   Google Scholar
• Schrödinger Release 2018-4: Glide. New York (NY): Schrödinger, LLC; 2018.
   Google Scholar
• Dash R, Hosen SZ, Karim MR, et al. In silico analysis of indole-3-carbinol and its metabolite DIM as EGFR tyrosine kinase inhibitors in platinum resistant ovarian cancer vis a vis ADME/T property analysis. J App Pharm Sci. 2015;5:073–078.
   Google Scholar
• Visualizer DS. 2017. Release 4.1. San Diego (CA): Accelrys Inc.
   Google Scholar
• Daina A, Michielin O, Zoete V. SwissADME: a free web tool to evaluate pharmacokinetics, drug-likeness and medicinal chemistry friendliness of small molecules. Sci Rep. 2017;7:42717.
   PubMed Web of Science ®Google Scholar
• Cheng F, Li W, Zhou Y, et al. 2012. admetSAR: a comprehensive source and free tool for assessment of chemical ADMET properties. J Chem Inf Model. 2012;52:3099–3105.
   PubMed Web of Science ®Google Scholar
• Dong J, Wang NN, Yao ZJ, et al. S. ADMETlab: a platform for systematic ADMET evaluation based on a comprehensively collected ADMET database. J Cheminformatics. 2018;10:29.
   PubMed Web of Science ®Google Scholar
• Filimonov DA, Lagunin AA, Gloriozova TA, et al. Prediction of the biological activity spectra of organic compounds using the PASS online web resource. Chem Heterocycl Comp. 2014;50:444–457.
   Web of Science ®Google Scholar
• Geronikaki A, Poroikov V, Hadjipavlou ‐Litina D, et al. Computer aided predicting the biological activity spectra and experimental testing of new thiazole derivatives. Quant Struct Act Relat. 1999;18:16–25.
   Google Scholar
• Zaretzki J, Bergeron C, Huang T, et al. RS-WebPredictor: a server for predicting CYP-mediated sites of metabolism on drug-like molecules. Bioinformatics. 2013;29:497–498.
   PubMed Web of Science ®Google Scholar
• Drwal M, Banerjee N, Dunkel P, et al. ProTox: a web server for the in silico prediction of rodent oral toxicity. Nucleic Acids Res. 2014;42:W53–W58.
   PubMed Web of Science ®Google Scholar
• Schrödinger Release 2018-4: Jaguar. New York (NY): Schrödinger, LLC; 2018.
   Google Scholar
• Lee C, Yang W, Parr RG. Development of the Colle-Salvetti correlation-energy formula into a functional of the electron density. Phys Rev B Condens Matter. 1988;37:785–789.
   PubMed Web of Science ®Google Scholar
• Becke AD. Density-functional exchange-energy approximation with correct asymptotic behavior. Phys Rev A Gen Phys. 1988;38:3098–3100.
   PubMedGoogle Scholar
• Pearson RG. Absolute electronegativity and hardness correlated with molecular orbital theory. Proc Natl Acad Sci U S A. 1986;83:8440–8441.
   PubMed Web of Science ®Google Scholar
• Parr RG, Yang W. Density-functional theory of atoms and molecules, Vol. 16 of International series of monographs on chemistry. New York: Oxford University Press; 1989.
   Google Scholar
• http://gohom.win/ManualHom/Schrodinger/Schrodinger_2015-2_docs/maestro/help_Maestro/tools_menu/ramachandran_panel.html. [accessed 2020 Feb 05].
   Google Scholar
• Yuriev E, Ramsland PA. Latest developments in molecular docking: 2010–2011 in review. J Mol Recognit. 2013;26:215–239.
   PubMed Web of Science ®Google Scholar
• Zhang X, Perez-Sanchez H, Lightstone FC. A comprehensive docking and MM/GBSA rescoring study of ligand recognition upon binding antithrombin. Curr Top Med Chem. 2017;17:1631–1639.
   PubMed Web of Science ®Google Scholar
• Sherman W, Day T, Jacobson M, et al. Novel procedure for modeling ligand/receptor induced fit effects. J Med Chem. 2006;49:534–553.
   PubMed Web of Science ®Google Scholar
• Aamir M, Singh V, Dubey K, et al. In silico prediction, characterization, molecular docking and dynamic studies on fungal SDRs as novel targets for searching potential fungicides against fusarium wilt in tomato. Front Pharmacol. 2018;9:1038.
   PubMed Web of Science ®Google Scholar
• Friesner RA, Murphy RB, Repasky MP, et al. Extra precision glide: docking and scoring incorporating a model of hydrophobic enclosure for protein − ligand complexes. J Med Chem. 2006;49:6177–6196.
   PubMed Web of Science ®Google Scholar
• Priyadarshini V, Pradhan D, Munikumar M, et al. Genome-based approaches to develop epitope-driven subunit vaccines against pathogens of infective endocarditis. J Biomol Struct Dyn. 2014;32:876–889.
   PubMed Web of Science ®Google Scholar
• Lipinski C, Lombardo A, Dominy F, et al. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv Drug Deliv Rev. 1997;23:3–25.
   Web of Science ®Google Scholar
• Gohlke H, Hendlich M, Klebe G. Knowledge-based scoring function to predict protein-ligand interactions. J Mol Biol. 2000;295:337–356.
   PubMed Web of Science ®Google Scholar
• Shoichet BK, McGovern SL, Wei B, et al. Lead discovery using molecular docking. Curr Opin Chem Biol. 2002;6:439–446.
   PubMed Web of Science ®Google Scholar
• Klebe G. 2015. Protein-ligand interactions as the basis for drug action. In: Scapin G, Patel D, Arnold E, editors. Multifaceted roles of crystallography in modern drug discovery. Dordrecht: Springer; p. 83–92.
   Google Scholar
• Lipinski CA. Lead-and drug-like compounds: the rule-of-five revolution. Drug Discov Today Technol. 2004;1:337–341.
   PubMedGoogle Scholar
• Pollastri MP. Overview on the rule of five. Curr Protoc Pharmacol. 2010;49:9–12.
   Google Scholar
• Li AP. Screening for human ADME/Tox drug properties in drug discovery. Drug Discov Today. 2001;6:357–366.
   PubMed Web of Science ®Google Scholar
• Guengerich FP. Cytochrome P-450 3A4: regulation and role in drug metabolism. Annu Rev Pharmacol Toxicol. 1999;39:1–17.
   PubMed Web of Science ®Google Scholar
• Glue P, Clement R. P. Cytochrome P450 enzymes and drug metabolism – basic concepts and methods of assessment. Cell Mol Neurobiol. 1999;19:309–323.
   PubMed Web of Science ®Google Scholar
• Dixit B. A review on the effects of CMPF binding with human serum albumin. Bioinformatics Rev. 2017;3:9–18.
   Google Scholar
• Radchenko EV, Dyabina AS, Palyulin VA, et al. Prediction of human intestinal absorption of drug compounds. Russ Chem Bull. 2016;65:576–580.
   Web of Science ®Google Scholar
• Wessel MD, Jurs PC, Tolan JW, et al. Prediction of human intestinal absorption of drug compounds from molecular structure. J Chem Inf Comput Sci. 1998;38:726–735.
   PubMedGoogle Scholar
• Basant N, Gupta S, Singh KP. Predicting human intestinal absorption of diverse chemicals using ensemble learning based QSAR modeling approaches. Comput Biol Chem. 2016;61:178–196.
   PubMed Web of Science ®Google Scholar
• Swierczewska M, Lee KC, Lee S. What is the future of PEGylated therapies? Expert Opin Emerg Drugs. 2015;20:531–536.
   PubMed Web of Science ®Google Scholar
• Smalling RW. Molecular biology of plasminogen activators: what are the clinical implications of drug design? Am J Cardiol. 1996;78:2–7.
   PubMed Web of Science ®Google Scholar
• Sahin S, Benet LZ. The operational multiple dosing half-life: a key to defining drug accumulation in patients and to designing extended release dosage forms. Pharm Res. 2008;25:2869–2877.
   PubMed Web of Science ®Google Scholar
• Sanguinetti M, Jiang C, Curran C, et al. A mechanistic link between an inherited and an acquird cardiac arrthytmia: HERG encodes the IKr potassium channel. Cell. 1995;81:299–307.
   PubMed Web of Science ®Google Scholar
• Aronov AM. Predictive in silico modeling for hERG channel blockers. Drug Discov Today. 2005;10:149–155.
   PubMed Web of Science ®Google Scholar
• Cheng A, Dixon SL. In silico models for the prediction of dose-dependent human hepatotoxicity. J Comput Aided Mol Des. 2003;17:811–823.
   PubMed Web of Science ®Google Scholar
• Xu JJ, Diaz D, O'Brien PJ. Applications of cytotoxicity assays and pre-lethal mechanistic assays for assessment of human hepatotoxicity potential. Chem Biol Interact. 2004;150:115–128.
   PubMed Web of Science ®Google Scholar
• Mortelmans K, Zeiger E. The Ames Salmonella/microsome mutagenicity assay. Mutat Res. 2000;455:29–60.
   PubMed Web of Science ®Google Scholar
• Holt MP, Ju C. Mechanisms of drug-induced liver injury. AAPS J. 2006;8:E48–E54.
   PubMed Web of Science ®Google Scholar
• Lagunin A, Stepanchikova A, Filimonov D, et al. PASS: prediction of activity spectra for biologically active substances. Bioinformatics. 2000;16:747–748.
   PubMed Web of Science ®Google Scholar
• United Nations. Economic Commission for Europe. Secretariat. 2005. Globally harmonized system of classification and labelling of chemicals (GHS). United Nations Publications.
   Google Scholar
• Tyzack JD, Mussa HY, Williamson MJ, et al. Cytochrome P450 site of metabolism prediction from 2D topological fingerprints using GPU accelerated probabilistic classifiers. J Cheminformatics. 2014;6:29.
   PubMed Web of Science ®Google Scholar
• Danielson P. B. The cytochrome P450 superfamily: biochemistry, evolution and drug metabolism in humans. Curr Drug Metab. 2002;3:561–597.
   PubMed Web of Science ®Google Scholar
• Matysiak J. Evaluation of electronic, lipophilic and membrane affinity effects on antiproliferative activity of 5-substituted-2-(2, 4-dihydroxyphenyl)-1, 3, 4-thiadiazoles against various human cancer cells. Eur J Med Chem. 2007;42:940–947.
   PubMed Web of Science ®Google Scholar
• Zhan CG, Nichols JA, Dixon DA. Ionization potential, electron affinity, electronegativity, hardness, and electron excitation energy: molecular properties from density functional theory orbital energies. J Phys Chem A. 2003;107:4184–4195.
   Web of Science ®Google Scholar
• Hoque MM, Halim MA, Sarwar MG, et al. Palladium‐catalyzed cyclization of 2‐alkynyl‐N‐ethanoyl anilines to indoles: synthesis, structural, spectroscopic, and mechanistic study. J Phys Org Chem. 2015;28:732–742.
   Web of Science ®Google Scholar
• Ayers PW, Parr RG, Pearson RG. Elucidating the hard/soft acid/base principle: a perspective based on half-reactions. J Chem Phys. 2006;124:194107.
   PubMed Web of Science ®Google Scholar